Bangalore:
Ranbaxy Laboratories said the company has no plans to delist from Indian bourses and it will remain a listed company.
"We have no intention to delist. Ranbaxy is an Indian diamond and will remain so," Ranbaxy chairman Tsutomu Une told reporters when asked if the company had any plans to delist.
Daiichi Sankyo of Japan has a 63.67 percent stake in the Indian drug manufacturer after it acquired the company in 2008 for Rs 22,000 crore from promoters led by Malvinder Singh.
FIIs hold 9.56 percent of the company's share while domestic institutions have a 10.91 percent stake, leaving a public holding of 15.86 percent.
The company is listed on the National and Bombay Stock Exchanges .
Magazine : 
.jpg "Unlocking Potential Redefining Potential & Redefining Excellence")
